Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Treatment options for transplant-ineligibile HL patients

Paul Jan Bröckelmann • 10 Jun 2022
EHA 2022
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Nivolumab Pembrolizumab
AERN

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses treatment options for transplant-ineligible Hodgkin lymphoma (HL) patients, highlighting the promise of targeted agents such as brentuximab vedotin, nivolumab and pembrolizumab, and the long-term benefits of these agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Paul Jan Bröckelmann

The growing role of anti-PD1 inhibitors in the frontline treatment of HL
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
The importance of individualizing treatment approaches in HL to improve patient outcomes
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
Recent clinical developments in the treatment landscape for older patients with HL
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
2:24
Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
Paul Jan Bröckelmann • 10 Dec 2025
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
1:13
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
Paul Jan Bröckelmann • 10 Dec 2025
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
5:31
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Paul Jan Bröckelmann • 10 Dec 2025
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Paul Jan Bröckelmann • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals